Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Sep;84(17):8953-8.
doi: 10.1128/JVI.00377-10. Epub 2010 Jun 16.

Impact of viral dose and major histocompatibility complex class IB haplotype on viral outcome in mauritian cynomolgus monkeys vaccinated with Tat upon challenge with simian/human immunodeficiency virus SHIV89.6P

Affiliations

Impact of viral dose and major histocompatibility complex class IB haplotype on viral outcome in mauritian cynomolgus monkeys vaccinated with Tat upon challenge with simian/human immunodeficiency virus SHIV89.6P

Aurelio Cafaro et al. J Virol. 2010 Sep.

Abstract

The effects of the challenge dose and major histocompatibility complex (MHC) class IB alleles were analyzed in 112 Mauritian cynomolgus monkeys vaccinated (n = 67) or not vaccinated (n = 45) with Tat and challenged with simian/human immunodeficiency virus (SHIV) 89.6P(cy243.) In the controls, the challenge dose (10 to 20 50% monkey infectious doses [MID(50)]) or MHC did not affect susceptibility to infection, peak viral load, or acute CD4 T-cell loss, whereas in the chronic phase of infection, the H1 haplotype correlated with a high viral load (P = 0.0280) and CD4 loss (P = 0.0343). Vaccination reduced the rate of infection acquisition at 10 MID(50) (P < 0.0001), and contained acute CD4 loss at 15 MID(50) (P = 0.0099). Haplotypes H2 and H6 were correlated with increased susceptibility (P = 0.0199) and resistance (P = 0.0087) to infection, respectively. Vaccination also contained CD4 depletion (P = 0.0391) during chronic infection, independently of the challenge dose or haplotype.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
(A) Frequency of MHC class IB haplotypes in 112 monkeys vaccinated with Tat (full-colored bars) or controls (zebra-striped bars). (B and C) Analysis of CD4 T cells in chronic infection in viremic macaques (n = 71) stratified by treatment (vaccinated, n = 37; controls, n = 34) and challenge dose (10 to 15 MID50, n = 58; 20 MID50, n = 13) (B) or class IB haplotype (H1, n = 26; H2, n = 24; H3, n = 25; H4, n = 25; H5, n = 8; H6, n = 9) (C). On the abscissa is reported the difference in CD4 T-cell counts pre- and postchallenge; least-squares means with 95% confidence intervals are shown (analysis of variance model).

Similar articles

Cited by

References

    1. Anastassopoulou, C. G., and L. G. Kostrikis. 2003. The impact of human allelic variation on HIV-1 disease. Curr. HIV Res. 1:185-203. - PubMed
    1. Bellino, S., V. Francavilla, O. Longo, A. Tripiciano, G. Paniccia, A. Arancio, V. Fiorelli, A. Scoglio, B. Collacchi, M. Campagna, A. Lazzarin, G. Tambussi, C. T. Din, R. Visintini, P. Narciso, A. Antinori, G. D'Offizi, M. Giulianelli, M. Carta, A. Di Carlo, G. Palamara, M. Giuliani, M. E. Laguardia, P. Monini, M. Magnani, F. Ensoli, and B. Ensoli. 2009. Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate. Rev. Recent Clin. Trials 4:195-204. - PubMed
    1. Borsetti, A., S. Baroncelli, M. T. Maggiorella, S. Bellino, S. Moretti, L. Sernicola, R. Belli, B. Ridolfi, S. Farcomeni, D. R. Negri, A. Cafaro, B. Ensoli, and F. Titti. 2008. Viral outcome of simian-human immunodeficiency virus SHIV-89.6P adapted to cynomolgus monkeys. Arch. Virol. 153:463-472. - PubMed
    1. Cafaro, A., A. Caputo, C. Fracasso, M. T. Maggiorella, D. Goletti, S. Baroncelli, M. Pace, L. Sernicola, M. L. Koanga-Mogtomo, M. Betti, A. Borsetti, R. Belli, L. Akerblom, F. Corrias, S. Butto, J. Heeney, P. Verani, F. Titti, and B. Ensoli. 1999. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat. Med. 5:643-650. - PubMed
    1. Cafaro, A., A. Caputo, M. T. Maggiorella, S. Baroncelli, C. Fracasso, M. Pace, A. Borsetti, L. Sernicola, D. R. Negri, P. ten Haaft, M. Betti, Z. Michelini, I. Macchia, E. Fanales-Belasio, R. Belli, F. Corrias, S. Butto, P. Verani, F. Titti, and B. Ensoli. 2000. SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine. J. Med. Primatol. 29:193-208. - PubMed

Publication types

MeSH terms

Substances